$LXRP --- Lexaria Bioscience 2021 Strategic Initiatives
Lexaria Bioscience Corp. (LXRP) (CSE:LXX) , a global innovator in oral drug delivery platforms, outlines its planned strategic initiatives for 2021 with a sharply enhanced focus on solutions related to the regulated pharmaceutical and medical market segments where it believes its patented technology will offer the highest value and utility.
Lexaria will concentrate its patented DehydraTECH drug delivery technology on four core areas of business with out-licensing strategies to existing drug manufacturers:
Heart disease including hypertension (high blood pressure) utilizing CBD;
Reduced-risk methods of delivering non-combusted nicotine;
Improving antiviral drug delivery for applications that include Covid-19, influenza, herpes, hepatitis and AIDS; and
Hemp-based CBD business-to-business ("B2B" applications for non-pharmaceutical consumer and therapeutic or medicinal products and prospective pharmaceutical indications beyond hypertension.
HEART DISEASE AND HYPERTENSION
The current global market size for drugs used to treat various heart diseases is $47.29 billion(1), and anticoagulants, antihypertensive, and antihyperlipidemic drugs comprise roughly 90% of these. Broad trends including aging populations and obesity are expected to contribute to growth in demand for heart disease-related drugs, where demand is expected to reach $63.96 billion by 2026.
Cardiovascular disease caused 840,678 deaths in the US during 2016 and more than one-third of all Americans suffer from some form of cardiovascular disease. The three leading companies in the cardiovascular drug market are thought to be Bristol-Myers Squibb; Pfizer, and Janssen Pharmaceuticals.
Lexaria has already demonstrated in a pilot human clinical study, published in a peer-reviewed medical journal in 2019, that its DehydraTECH processed cannabidiol (CBD) was associated with a statistically significant slight decrease in human blood pressure, theorized to have occurred as a result of the known vasodilatory potential of CBD. As a complex fat-soluble molecule, generic CBD is known to have poor absorption characteristics, such that typically only about 6% of what is orally ingested actually finds its way into blood circulation. Lexaria's technology has shown an ability to increase this absorption into the blood circulation by between 100% to 500%.
Lexaria is expecting to commence a second exploratory human clinical study intended to corroborate and expand on the findings of the original pilot study. Clinical test articles have been manufactured and are ready for shipment to the clinical site pending regulatory clearance for importation purposes. If this study is successful, Lexaria will then begin systematic outreach to some of the world's participants in the cardiovascular disease drug industry to introduce DehydraTECH's enhancement technology.
Lexaria's DehydraTECH is patent granted in the European Union and Australia for treatment of heart disease utilizing CBD, and the Company continues to seek international expansion of its patent protection utilizing CBD throughout the world.
https://ir.lexariabioscience.com/news-events/...nitiatives
https://www.fortunebusinessinsights.com/indus...ket-100379
Read More: https://investorshangout.com/post/view?id=596...z6dy8Y3S5x
2
